{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:23:56Z","timestamp":1785864236686,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jmii.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T09:20:15Z","timestamp":1720948815000},"page":"760-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6756-6285","authenticated-orcid":false,"given":"Yu-Ting","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-2064","authenticated-orcid":false,"given":"Chia-Jui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-5488","authenticated-orcid":false,"given":"Yeon-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2775-3315","authenticated-orcid":false,"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Seong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yeh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-a","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2093-3628","authenticated-orcid":false,"given":"Sun Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2024.07.003_bib1","series-title":"Global HIV & AIDS statistics \u2013 fact sheet","year":"2023"},{"key":"10.1016\/j.jmii.2024.07.003_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25219","article-title":"Trends in mortality among ART-treated HIV-infected adults in the Asia-pacific region between 1999 and 2017: results from the TREAT Asia HIV observational database\u00a0(TAHOD) and Australian HIV observational database\u00a0(AHOD) of IeDEA Asia-Pacific","volume":"22","author":"Jung","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jmii.2024.07.003_bib3","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1097\/QAI.0000000000001258","article-title":"HIV and aging: demographic change in the Asia-Pacific region","volume":"74","author":"Puhr","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2024.07.003_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2024.07.003_bib5","series-title":"Guidelines version 12.0","year":"2023"},{"key":"10.1016\/j.jmii.2024.07.003_bib6","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2024"},{"key":"10.1016\/j.jmii.2024.07.003_bib7","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/pathogens10101332","article-title":"HIV and aging: overcoming challenges in existing HIV guidelines to provide patient-centered care for older people with HIV","volume":"10","author":"Sangarlangkarn","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.jmii.2024.07.003_bib8","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.07.003_bib9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3947\/ic.2021.0305","article-title":"Summary of 2021 clinical guidelines for the diagnosis and treatment of HIV\/AIDS in HIV-infected Koreans","volume":"53","year":"2021","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jmii.2024.07.003_bib10","series-title":"National HIV programme: recommendations for the use of antiretroviral therapy (ART) in adults living in Singapore","year":"2023"},{"key":"10.1016\/j.jmii.2024.07.003_bib11","series-title":"Guidelines for diagnosis and treatment of HIV\/AIDS. Sixth edition (2020 revision)","year":"2023"},{"key":"10.1016\/j.jmii.2024.07.003_bib12","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jiac.2022.07.005","article-title":"Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan","volume":"28","author":"Wang","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jmii.2024.07.003_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245185","article-title":"A comparison of medication adherence and viral suppression in antiretroviral treatment-naive patients with HIV\/AIDS depending on the drug formulary","volume":"16","author":"Oh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2024.07.003_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106631","article-title":"Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens","volume":"60","author":"Chen","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2024.07.003_bib15","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2024.07.003_bib16","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.07.003_bib17","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2024.07.003_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jmii.2024.07.003_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2024.07.003_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/hiv.13386","article-title":"Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: a pooled analysis from three international phase III randomized trials","volume":"24","author":"Avihingsanon","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2024.07.003_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.11622\/smedj.2021174","article-title":"Recommendations for the use of antiretroviral therapy in adults living with HIV in Singapore","volume":"65","author":"Choy","year":"2024","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jmii.2024.07.003_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2024.07.003_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice","volume":"30","author":"Armenia","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jmii.2024.07.003_bib24","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/IDR.S331647","article-title":"Outcomes after switching to BIC\/FTC\/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study","volume":"14","author":"Chang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2024.07.003_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jmii.2024.07.003_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40121-022-00734-5","article-title":"Comparison of virological efficacy of DTG\/ABC\/3TG and B\/F\/TAF regimens and discontinuation patterns in persons living with advanced HIV in the era of rapid ART: a retrospective multicenter cohort study","volume":"12","author":"Lee","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jmii.2024.07.003_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","article-title":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation","volume":"126","author":"Tsai","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jmii.2024.07.003_bib28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3947\/ic.2021.0127","article-title":"HIV-related stigma reduction in the era of undetectable equals untransmittable: the South Korean perspective","volume":"53","author":"Choi","year":"2021","journal-title":"Infect Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jmii.2024.07.003_bib29","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1097\/QAI.0000000000000262","article-title":"HIV and noncommunicable diseases: the Asian perspective","volume":"67","author":"Ananworanich","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2024.07.003_bib30","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts","author":"Esser","year":"202425440","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2024.07.003_bib31","series-title":"Biktarvy tablet product information (Korea)","year":"2020"},{"key":"10.1016\/j.jmii.2024.07.003_bib32","series-title":"Biktarvy tablets prescribing information (Singapore)","year":"2023"},{"key":"10.1016\/j.jmii.2024.07.003_bib33","series-title":"Biktarvy tablets product information (Taiwan)","year":"2023"},{"key":"10.1016\/j.jmii.2024.07.003_bib34","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2024.07.003_bib35","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/v15061222","article-title":"Immune reconstitution and safe metabolic profile after the switch to bictegravir\/emtricitabine\/tenofovir alafenamide fumarate among virologically controlled PLWH: a 96 week update from the BICTEL cohort","volume":"15","author":"Lazzaro","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jmii.2024.07.003_bib36","series-title":"Strategies to prevent weight gain among adults. Comparative effectiveness reviews. No. 97. AHRQ publication No. 13-EHC029-EF","author":"Hutfless","year":"2013"},{"key":"10.1016\/j.jmii.2024.07.003_bib37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jgar.2023.10.012","article-title":"Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"36","author":"Hsu","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jmii.2024.07.003_bib38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jmii.2024.07.003_bib39","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.07.003_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.orcp.2020.05.004","article-title":"Self-quarantine and weight gain related risk factors during the COVID-19 pandemic","volume":"14","author":"Zachary","year":"2020","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.jmii.2024.07.003_bib41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jmii.2023.07.013","article-title":"Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound","volume":"56","author":"Chen","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2024.07.003_bib42","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jmii.2022.10.001","article-title":"Impact of coronavirus disease 2019 on the HIV testing and health care delivery at a university hospital in Taiwan, 2020\u20132021","volume":"55","author":"Wu","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2024.07.003_bib43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jmii.2023.01.015","article-title":"Patient-reported outcomes among virally suppressed people living with HIV after switching to co-formulated bictegravir, emtricitabine and tenofovir alafenamide","volume":"56","author":"Chen","year":"2023","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224001142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224001142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T03:03:19Z","timestamp":1726801399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118224001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1684118224001142"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2024.07.003","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}